Disease · MONDO_0007113
Trials16
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 16 of 16
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03882918 | An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome | Phase 3 | 141 | 2025-07-18 | Angelman Syndrome | GABOXADOL | Its record names the disease | ClinicalTrials.gov |
| NCT04106557 | A Study of OV101 in Individuals With Angelman Syndrome (AS) | Phase 3 | 104 | 2024-01-08 | Primary Disease or Condition Being Studied: Angelman Syndrome (AS) | GABOXADOL | Its record names the disease | ClinicalTrials.gov |
| NCT00348933 | Dietary Supplements for the Treatment of Angelman Syndrome | Not applicable | 90 | 2012-09-24 | Angelman Syndrome, Nervous System Diseases | BETAINE, CREATINE, LEVOMEFOLATE CALCIUM, LEVOMEFOLIC ACID, VITAMIN B12 | Its record names the disease | ClinicalTrials.gov |
| NCT02996305 | A Study in Adults and Adolescents With Angelman Syndrome (STARS) | Phase 2 | 88 | 2022-03-31 | Angelman Syndrome | GABOXADOL | Its record names the disease | ClinicalTrials.gov |
| NCT01281475 | A Trial of Levodopa in Angelman Syndrome | Phase 2/3 | 67 | 2017-01-13 | Angelman Syndrome | LEVODOPA | Its record names the disease | ClinicalTrials.gov |
| NCT01531582 | Minocycline in the Treatment of Angelman Syndrome | Not applicable | 25 | 2023-04-18 | Angelman Syndrome | MINOCYCLINE | Its record names the disease | ClinicalTrials.gov |
| NCT00829439 | Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome | Phase 1 | 16 | 2016-11-21 | Angelman Syndrome | CARBIDOPA, LEVODOPA | Its record names the disease | ClinicalTrials.gov |
| NCT07605429 | BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome. | Phase 3 | 165 | Angelman Syndrome | RUGONERSEN | Its record names the disease | ClinicalTrials.gov | |
| NCT06914609 | REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome | Phase 3 | 156 | Angelman Syndrome | OBUDANERSEN SODIUM | Its record names the disease | ClinicalTrials.gov | |
| NCT04428281 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS) | Phase 1 | 74 | Angelman Syndrome | RUGONERSEN | Its record names the disease | ClinicalTrials.gov | |
| NCT05127226 | HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome | Phase 1/2 | 71 | Angelman Syndrome | OBUDANERSEN SODIUM | Its record names the disease | ClinicalTrials.gov | |
| NCT05630066 | A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. | Phase 2 | 48 | Angelman Syndrome | ALOGABAT | Its record names the disease | ClinicalTrials.gov | |
| NCT02056665 | Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome | Phase 2 | 32 | Angelman Syndrome | MINOCYCLINE | Its record names the disease | ClinicalTrials.gov | |
| NCT05011851 | An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome | Phase 2 | 17 | Angelman Syndrome | NNZ-2591 | Its record names the disease | ClinicalTrials.gov | |
| NCT03235037 | Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome | Not applicable | 10 | Angelman Syndrome | LEVODOPA | Its record names the disease | ClinicalTrials.gov | |
| NCT07136454 | Expanded Access/Compassionate Use of Rugonersen in Patients With Angelman Syndrome | Angelman Syndrome | RUGONERSEN | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007113/trials